oral selective DNA-PK kinase inhibitor
synergy with radiotherapy in model
from library screen
Journal of Medicinal Chemistry
Bayer AG, Berlin, Germany
BAY-8400
The Bayer DNA-PK inhibitor, BAY-8400, is an orally active and selective DNA-PK kinase inhibitor that synergistically enhances the efficacy of radiotherapeutics in xenograft models. The program started with a campaign…